Onco Actu du 21 novembre 2018

	2. Etiologie
Scientists uncover why testicular cancer runs in families [Institute of Cancer Research] To make their discovery, published in European Urology, the researchers made an in-depth comparison between DNA from around 4,000 men with testicular germ cell tumour (TGCT) and 12,000 men who did not develop it.
	4. Dépistage, diagnostic et pronostic
Evaluating Susceptibility to Pancreatic Cancer [ASCO] An ASCO provisional clinical opinion (PCO) offers timely clinical direction to ASCO’s membership and other health care providers. This PCO addresses identification and management of patients and family members with possible predisposition to pancreatic adenocarcinoma.
	4.1 Dép., diag. & prono. - Prostate
Online tool can help men make prostate cancer treatment choices [Reuters] “This tool is not meant to replace the shared decision-making process but rather to augment that process by helping patients focus their preparation on likely treatment options prior to meeting with their urologist,” Singh said.
	4.11 Dép., diag. & prono. - Ovaire
New Blood Test Detects Early Stage Ovarian Cancer [University of Adelaide] A paper published this month in Biochemical and Biophysical Research Communications has shown that the new test detected significant levels of the cancer glycan in blood samples from over 90% of women with stage 1 ovarian cancer and in 100% of samples from later stages of the disease, but not in any of the samples from healthy controls.
News release far too rosy/conflicted for small study on ovarian cancer test [HealthNewsReview] Cost is not mentioned and, according to the published study, the high costs of the sensors used in detecting the cancer have proven to be a major drawback.
	4.12 Biopsies liquides
Guardant Health Collecting Data to Make Case for 'Blood-First' Cancer Testing Paradigm [Genome Web] The germ of this will come from a study Guardant has been conducting called NILE (Noninvasive vs. Invasive Lung Evaluation), which is designed to determine the "non-inferiority" of cell-free DNA-based genotyping as it pertains to the detection of seven National Comprehensive Cancer Network-recommended biomarkers in first-line, treatment-naïve, non-squamous non-small cell lung cancer.
	4.9 Dép., diag. & prono. - Sein
Breast cancer screening should be offered to women in late 70s, experts say following major study [The Telegraph] For the new study, experts at Elizabeth Wende Breast Care in Rochester, New York analysed data from 76,885 screening mammography examinations between 2007 and 2017 on patients with an average age of 80.
	5.1 Traitements - Pré-clinique
Targeting inflammation could help treat drug-resistant bowel cancer [Institute of Cancer Research] By comparing the genetics of trametinib-resistant cancer cells with those that respond to treatment, the team discovered that the resistant cells had higher levels of activity in their genes related to inflammation.
Study Finds Source of PARP Inhibitor Drug Resistance [Dana-Farber Cancer Institute] Using high-grade serious ovarian cancer (HGSOC) cells with defective BRCA1, the investigators shut down 17,000 genes, one at a time, to determine which were responsible for resistance to PARP inhibitors. The most notable was one discovered was one that generates a protein called DYNLL1.
	5.10 Traitements - Essais
Olaparib after Initial Treatment Delays Ovarian Cancer Progression [NCI] The findings from the SOLO-1 trial are practice changing, Isabelle Ray-Coquard, M.D., Ph.D., of Claude Bernard University in Lyon, France, said in a news release.
	5.12.5 Immunothérapies - Pharma
Pharma Roche yanks Tecentriq kidney cancer applications as Merck, Pfizer speed toward approvals [FiercePharma] “Based on data we have available, we believe that the combination of Tecentriq and Avastin may play a role in the treatment of advanced kidney cancer, which remains an area of high unmet medical need where people need more treatment options,” she added.
Bavencio falls short in ovarian cancer study [BiopharmaDive] The failure of Bavencio (avelumab) in ovarian cancer isn't entirely a surprise, as checkpoint inhibitors have had less success in this tumor type than in others like lung cancer and melanoma. None of the currently approved checkpoint inhibitors are cleared for use in ovarian cancer in the U.S.
	5.2.1 Pharma - Partenariats
LEO Pharma inks $760M rare skin disease R&D deal with PellePharm [FierceBiotech] Going forward, PellePharm’s previously announced phase 3 trial aims to enroll 150 blinded participants, with patidegib 2% gel being applied to the face twice daily, compared to the gel vehicle alone. The companies hope to see it not only treat but prevent new basal-cell carcinomas.
	5.3 Traitements - FDA, EMA, NICE...
Most FDA required post-marketing drug studies are missing [EPR] A study from Boston Children’s Hospital finds that only about a third of these mandatory trials were completed within an average of seven years. As a result, most new drug labels continue to lack information needed for use in children, and most FDA-approved medications remain untested in children.
Workshop on how to better support medicine developers in the generation and preparation of quality data packages for PRIME and Breakthrough Therapy applications [EMA] The event, which is a joint collaboration between EMA and the US Food and Drug Administration (FDA), intends to explore opportunities and best practices between the agencies and industry to further facilitate the successful development and authorisation of priority medicines.
FDA's Woodcock: 'The clinical trial system is broken' [BioparmaDive] The director for the Center for Drug Evaluation and Research pitched platform trials with master protocols, which she argued can more efficiently answer clinical questions. While this design can require competitors to work together, Woodcock said she has seen a "groundswell" of recent support.
	5.8.2 ASH - Pharma
AbbVie to Highlight Breadth of Innovative Science and Ongoing Commitment to Blood Cancer Patients with New Data From Studies of Ibrutinib and Venetoclax at 2018 American Society of Hematology Annual Meeting & Exposition [AbbVie] Notable data will be presented on the lack of CLL progression after seven years in patients treated with ibrutinib, marking the longest follow-up study for a Bruton's tyrosine kinase inhibitor.
Data from Phase III MAIA Study of Daratumumab Accepted for Presentation at Annual Meeting of American Society of Hematology [Genmab] Data from Phase III MAIA study in front line multiple myeloma accepted as Late-breaking Abstract for oral presentation at ASH Annual Meeting.
	6.3 Associations/Fondations
The Pancreatic Cancer Collective awards $7 million in first-round “New Therapies Challenge” Grants [Stand Up to Cancer] These teams are the first projects funded under the Pancreatic Cancer Collective launched this spring to accelerate pancreatic cancer research and improve patient outcomes for pancreatic cancer, which is one of the deadliest cancers, with a five-year survival rate of only 8 percent, according to the National Cancer Institute.
	6.6 Publications
Q&A: John Ioannidis Talks Transparency in Biomedical Literature [The Scientist] The Stanford University researcher discusses a new study on measures such as data sharing and funding disclosures.